Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 2/2001

01-03-2001

Intravenous Amiodarone Decreases the Duration of Atrial Fibrillation Associated with Acute Myocardial Infarction

Authors: Dimitrios A. Kontoyannis, Maria I. Anastasiou-Nana, Sofocles A. Kontoyannis, Afrodite K. Zaga, John N. Nanas

Published in: Cardiovascular Drugs and Therapy | Issue 2/2001

Login to get access
Metadata
Title
Intravenous Amiodarone Decreases the Duration of Atrial Fibrillation Associated with Acute Myocardial Infarction
Authors
Dimitrios A. Kontoyannis
Maria I. Anastasiou-Nana
Sofocles A. Kontoyannis
Afrodite K. Zaga
John N. Nanas
Publication date
01-03-2001
Publisher
Kluwer Academic Publishers
Published in
Cardiovascular Drugs and Therapy / Issue 2/2001
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1023/A:1011127030014

Other articles of this Issue 2/2001

Cardiovascular Drugs and Therapy 2/2001 Go to the issue

OriginalPaper

The EUROPA Trial: Design, Baseline Demography and Status of the Substudies

OriginalPaper

CHF-1024, A DA2/α2 Agonist, Blunts Norepinephrine Excretion and Cardiac Fibrosis in Pressure Overload

Editorial Introduction

cDNA Arrays: The Ups and Downs

OriginalPaper

Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure

OriginalPaper

The Effects of Streptokinase and Hydroxyethyl Starch on in vitro Clot Disruption by Ultrasound

OriginalPaper

Neurocardiogenic Syncope in Selected Pediatric Patients—Natural History during Long-Term Follow-Up and Effect of Prophylactic Pharmacological Therapy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits